神经生长因子治疗非动脉炎性前部缺血性视神经病变的临床效果

doi:10.3760/cma.j.cn115909-20191228-00353

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (743 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract Objective: To observe the effects of nerve growth factor (NGF) in the treatment of non-arteritic anterior ischemic optic neuropathy (NA-AION). Methods: This was a prospective, randomized, controlled study. Fifty-eight NA-AION patients (58 eyes) admitted to Lianshui County People's Hospital from July 2016 to June 2019 were selected, and then were divided into a control group and an observation group based on the random numerical table method. The control group (29 patients with 29 eyes) were given glucocorticoid hormones, Huoxue Tongluo granules and an anisodine compound. While the observation group (29 patients with 29 eyes), were treated with NGF in addition to the treatment plan previously described. The total effective rate, best corrected visual acuity (BCVA), the 30-degree visual-field examination mean deviation (MD) and the disc retinal nerve fiber layer (RNFL) thickness of the two groups were compared. Data were analyzed by the Fisher's exact test, a t test and a non-parametric test. Results: After treatment, the total effective rate for the observation group was significantly higher than that for the control group (P=0.04), the percentage of BCVA above 0.1 in the observation group was significantly higher than that in the control group (P<0.001), and both the MD and RNFL thickness in the observation group were significantly lower than those in the control group (t=2.59, P=0.01; t=4.86, P<0.001). There were no obvious adverse reactions for either group after treatment. Conclusions: The treatment of NA-AION with NGF can obtain a better effective rate, improve the patient's vision, improve the visual field and reduce RNFL thickness.

Key words： nerve growth factor non-arteritic anterior ischemic optic neuropathy best corrected visual acuity mean deviation retinal nerve fiber layer

Received: 28 December 2019

PACS:

Fund: 333 High-Level Talent Training Project in Jiangsu Province [(2018)Ⅲ-1063]

Corresponding Authors: Hongwei Zhou, Department of Ophthalmology, Lianshui County People's Hospital, Huai'an 223400, China (Email: leave0307@163.com)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.cn115909-20191228-00353 OR https://www.cjoovs.com/EN/Y2020/V22/I10/781

[1]	Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res, 2009, 28(1): 34-62. DOI: 10.1016/j.preteyeres.2008.11.002.
[2]	中华医学会眼科学分会神经眼科学组. 我国非动脉炎性前部缺血性视神经病变诊断和治疗专家共识(2015 年). 中华眼科杂志, 2015, 51(5): 323-326. DOI: 10.3760/cma. j.issn.0412-4081.2015.05.002.
[3]	陈彦, 郑志斌, 黄慧慧. 灯盏花素联合神经生长因子治疗缺血性视神经病变患者的临床效果. 中国生化药物杂志, 2017, 37(3): 172-174. DOI: 10.3969/j.issn.1005-1678.2017.03.052.
[4]	中国神经生长因子临床应用专家共识协作组. 神经生长因子 (恩经复)临床应用专家共识. 中华神经医学杂志, 2012, 11(4): 416-420. DOI: 10.3760/cma.j.issn.1671-8925.2012.04.021.
[5]	Mesentier-Louro LA, De Nicolò S, Rosso P, et al. Timedependent nerve growth factor signaling changes in the rat retina during optic nerve crush-induced degeneration of retinal ganglion cells. Int J Mol Sci, 2017, 18(1): 98. DOI: 10.3390/ ijms18010098.
[6]	张颖, 张慧芝, 张英杰. 复方樟柳碱联合鼠神经生长因子治疗缺血性视神经病变临床观察. 中国实用神经疾病杂志, 2017, 20(2): 36-38. DOI: 10.3969/j.issn.1673-5110.2017.02.014.
[7]	毛春洁, 张静楷, 颜华. 神经生长因子治疗后天性麻痹性斜视的临床效果. 中华眼视光学与视觉科学杂志, 2018, 20(10): 599-603. DOI: 10.3760/cma.j.issn.1674-845x.2018.10.005.
[8]	黎玥, 徐建江. 神经生长因子对单纯疱疹病毒性角膜炎的治疗作用与机制. 中国眼耳鼻喉科杂志, 2017, 17(6): 436-440. DOI: 10.14166/j.issn.1671-2420.2017.06.016.
[9]	葛坚, 王宁利. 眼科学. 3版. 北京: 人民卫生出版社, 2015: 363.
[10]	Chen D, Peng C, Xie X, et al. Low dose of anisodine hydrobromide induced neuroprotective effects in chronic cerebral hypoperfusion rats. CNS Neurol Disord Drug Targets, 2017, 16(10): 1111-1119. DOI: 10.2174/1871527316666171026 114043.
[11]	任勇刚, 雷新平, 柳双宝, 等. 曲安奈德联合鼠神经生长因子治疗合并糖尿病的非动脉炎性前部缺血性视神经病变. 临床眼科杂志, 2015, 23(1): 36-38. DOI: 10.3969/ j.issn.1006-8422.2015.01.011.
[12]	万贝贝, 徐军. 鼠神经生长因子联合复方樟柳碱治疗非动脉炎性前部缺血性视神经病变. 国际眼科杂志, 2015, 15(10): 1720-1722. DOI: 10.3980/j.issn.1672-5123.2015.10.11.
[13]	Birer S, Arda H, Kilic D, et al. Systemic oxidative stress in nonarteritic anterior ischemic optic neuropathy. Eye (Lond), 2019 , 33(7): 1140-1144. DOI: 10.1038/s41433-019-0388-0.
[14]	Pellegrini M, Giannaccare, Bernabei F, et al. Choroidal vascular changes in arteritic and nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol, 2019, 205: 43-49. DOI: 10.1016/ j.ajo.2019.03.028.
[15]	吕航, 王启常, 唐罗生. 神经生长因子玻璃体腔注射对早期糖尿病大鼠视网膜神经节细胞的保护作用 . 中华实验眼科杂志, 2019, 37(6): 425-431. DOI: 10.3760/cma. j.issn.2095-0160.2019.06.005.
[16]	赵明. NGF对视神经挫伤患者视力和VEP的影响及安全性分析. 国际眼科杂志, 2018, 18(2): 316-318. DOI: 10.3980/ j.issn.1672-5123.2018.2.28.
[17]	Minnone G, De Benedetti F, Bracci-Laudiero L. NGF and its receptors in the regulation of inflammatory response. Int J Mol Sci, 2017, 18(5): 1028. DOI: 10.3390/ijms18051028.
[18]	Hayreh SS. Controversies on neuroprotection therapy in nonarteritic anterior ischaemic optic neuropathy. Br J Ophthalmol, 2019, 104(2): 153-156. DOI: 10.1136/bjophthalmol-2019-314656.

[1]	. [J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2023, 25(8): 0-.